ArticleWorld journal of surgery2011
Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.
Article in World journal of surgery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 3 syntheses or guidelines pooled it, 213 citations in OpenAlex.
- 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Guideline
- Outcomes and effectiveness of active surveillance for low-risk papillary thyroid carcinoma: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Pooled it
- Risk Factors for Central Lymph Node Metastasis in CN0 Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.PloS one · 2015Pooled it
- Active surveillance for low-risk papillary thyroid carcinoma: Integrating guidelines, emerging evidence, and directions.iScience · 2026Review
- Ultrasound Imaging Criteria and Protocols for Active Surveillance of Low-Risk Thyroid Cancer: A Review of International Consensus Guidelines.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Predicting central lymph node metastasis in papillary thyroid carcinoma combined with Hashimoto's thyroiditis: a preoperative study.BMC cancer · 2025Article
- Clinicopathological and molecular characteristics of papillary thyroid carcinoma in adolescent and young adult patients.Endocrine journal · 2025Article
- Long-term outcomes of active surveillance for low-risk papillary thyroid carcinoma: Progression patterns and tumor calcification.World journal of surgery · 2025Article
- Age- and sex-specific impact on the progression of low-risk papillary thyroid carcinoma under active surveillance: a meta-analysis.Frontiers in oncology · 2025Review
- Standardized Ultrasound Evaluation for Active Surveillance of Low-Risk Thyroid Microcarcinoma in Adults: 2024 Korean Society of Thyroid Radiology Consensus Statement.Journal of the Korean Society of Radiology · 2024Review
- Standardized Ultrasound Evaluation for Active Surveillance of Low-Risk Thyroid Microcarcinoma in Adults: 2024 Korean Society of Thyroid Radiology Consensus Statement.Korean journal of radiology · 2024Article
- Development of a nomogram for prediction of central lymph node metastasis of papillary thyroid microcarcinoma.BMC cancer · 2024Article
- Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines.Endocrinology and metabolism (Seoul, Korea) · 2024Review
- Risk nomogram for papillary thyroid microcarcinoma with central lymph node metastasis and postoperative thyroid function follow-up.Frontiers in endocrinology · 2024Article
- Clinical factors for choosing active surveillance: an analysis of papillary thyroid microcarcinoma patients with recurrence.European thyroid journal · 2023Article
- Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer.Cancer medicine · 2023Article
- Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.World journal of surgery · 2023Article
- Factors of Central Lymph Node Metastasis in Papillary Thyroid Cancer Based on C-TIRADS Analysis.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2023Article
- Migration of Risk Classification Between the JAES Versus ATA guidelines for Papillary Thyroid Carcinoma.World journal of surgery · 2023Article
- Patient-Reported Outcomes in Patients with Low-Risk Papillary Thyroid Carcinoma: Cross-Sectional Study to Compare Active Surveillance and Immediate Surgery.World journal of surgery · 2023Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic strategy for patients with differentiated thyroid carcinoma (DTC) in Japan has differed from that in Western countries. Total thyroidectomy followed by radioactive iodine (RAI) ablation has been a standard therapy in Western countries, while limited thyroidectomy has been widely accepted in Japan. We newly established guidelines for clinical practice in treating thyroid tumors based on evidence from previous publications and the accumulation of data from patients in Japan. We present our therapeutic recommendations for DTC patients based on these guidelines.
methodsFrom the 55 clinical questions (CQ) in our guideline, we selected CQ regarding the treatment of DTC. We commented on each and compared it with the corresponding regions in Western guidelines.
resultsFor papillary carcinoma, we strongly or moderately recommend total thyroidectomy for patients with tumors larger than 4 cm, clinical node metastasis, distant metastasis, or significant extrathyroid extension, while hemithyroidectomy is acceptable for T1N0M0 patients. In contrast to Western guidelines, routine central compartment dissection is recommended for papillary carcinoma in our guidelines. Completion total thyroidectomy is recommended for patients who were scheduled for hemithyroidectomy under a preoperative diagnosis of follicular neoplasm and were pathologically confirmed as having follicular carcinoma if the pathological diagnosis indicated widely invasive carcinoma or carcinoma having poorly differentiated components. RAI ablation is also recommended for DTC with aggressive clinicopathological features, but its indication is narrower than that in Western guidelines, not only because of the limitations on RAI, but also because it is our policy that patients without high-risk features do not require RAI ablation.
conclusionIt is important to treat DTC patients individually according to their clinicopathological features rather than uniformly. We hope that policies regarding the treatment of DTC patients in Western countries and Japan will find the optimal compromise in the future, leading to the best treatments for patients with thyroid carcinoma all over the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.